Is ABT a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on FreeStyle Libre: A Platform, Not Just a Product, with revenue (ttm) at ~$46.6 billion (Q2 2026 sales $12.59 billion, +13% reported, +4.8% comparable). The bear case rests on the most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements. Analysts covering it are spread from $103.00 to $135.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $103.00, -1.8% from the $104.89 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

FreeStyle Libre: A Platform, Not Just a Product. FreeStyle Libre exceeded $7.5 billion in 2025 annual sales and grew roughly 19-20% organically in H1 2025, making it the dominant revenue engine within Medical Devices. The most optimistic analyst target on ABT is $135.00, +28.7% from the $104.89 price. That figure is only reachable if this thesis works close to its best case.

The most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements. Abbott has started to narrow this exposure, reaching agreements in August 2026 to resolve a portion of the preterm-formula litigation and an agreement with the Department of Justice in September 2026 on claims tied to the 2022 recall, but the remaining liability is still open-ended. Integration of the approximately $21 billion Exact Sciences acquisition introduces execution risk, amortization and elevated SGA costs: GAAP EPS was only $0.53 in Q2 2026 against adjusted EPS of $1.31, and the trailing GAAP P/E is about 34x even though the forward multiple is about 17x. Organic growth also slowed to 4.8% in Q2 2026 on a comparable basis, below the full-year 6.5-7.5% guide. Foreign exchange swings move reported international revenue by several percentage points, and any meaningful dollar strengthening would pressure reported results disproportionately given Abbott's broad non-US exposure. Competitive disruption in continuous glucose monitoring from DexCom and emerging players, along with pricing pressure from government payers and the Inflation Reduction Act, represent structural long-term headwinds. The most pessimistic published target is $103.00, -1.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Abbott Laboratories is a global healthcare company headquartered in North Chicago, Illinois, that discovers, develops, manufactures, and sells health care products in more than 160

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (FreeStyle Libre: A Platform, Not Just a Product) stalling in the reported numbers rather than in the narrative, the risk above (the most acute near-term risk is infant formula litigation: juries have delivered verdicts including a $53 million compensatory award in late March 2026 and a separately upheld $495 million verdict, with hundreds of additional NEC-related cases pending, and a securities class action filed in 2026 adds a parallel legal exposure track targeting alleged investor misstatements) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Abbott is a global healthcare company operating in four segments: Medical Devices (largest, led by the FreeStyle Libre glucose monitor and cardiovascular products), Diagnostics (laboratory and point-of-care tests, plus Cologuard cancer screening since the 2026 Exact Sciences deal), Nutrition (Similac infant formula, Ensure adult nutrition), and Established Pharmaceuticals (branded generics in emerging markets). It serves patients in more than 160 countries and employs roughly 122,000 people worldwide.

That depends on your investment horizon and risk tolerance; Walnut does not give investment advice. ABT's Medical Devices segment grew 8.4% on a comparable basis in Q2 2026, management raised full-year EPS guidance in July, and the stock trades near 17x forward earnings after falling about 16% in 2026. However, infant formula litigation that is only partly settled, Exact Sciences integration complexity, and slower overall organic growth (4.8% in Q2) are real uncertainties. Investors weigh these factors differently based on their goals.

Yes. Abbott has raised its dividend for more than 53 consecutive years, qualifying it as a Dividend King, and in September 2026 declared its 411th consecutive quarterly dividend. The current quarterly dividend is $0.63 per share (annualized $2.52), a yield of about 2.4% as of October 16, 2026. Trailing free cash flow of about $7.2 billion covers the payout, although the payout ratio against GAAP earnings has risen to roughly 79% because acquisition costs have depressed reported profit.